This translational research project will develop quantitative imaging bionnarkers for assessing therapeutic response in Sarcoma using advanced quantitative imaging approaches in PET and MRl.
In Specific Aim #1, dynamic contrast enhanced (DCE) and diffusion weighted (DW) MRl will be evaluated in a multi-center clinical trial of patients with soft tissue sarcoma ofthe extremities receiving neoadjuvant chemotherapy prior to surgical resection. DCE- and DW-MRI imaging will be performed prior to and at the conclusion of chemotherapy to evaluate the correlation between treatment response assessed with MRl parameters (permeability, perfusion, and diffusion) and tumor histopathology obtained from surgical resection. Exploratory analysis will also be performed to compare imaging and pathologic response with clinical outcome.
In Specific Aim #2, two novel PET apoptosis probes (18F-ML-10 and 1241-Diannexin) will be evaluated and compared to existing PET probes for glucose metabolism (FDG) and cellular proliferation (FLT). Similar strategies will be employed in Specific Aim #3 to evaluate hwo novel PET probes for angiogenesis (i8F-FPP(RgD) and 892R-beYaci?Ufnat)). Preclinical microPET/CT imaQlno studiQS will bQ performed in several sarcoma mouse models using the comprehensive panel of PET probes in longitudinal treatment studies of various therapeutic agents. Correlations with tumor histopathology will be performed to validate the imaging assessments. In addition, DCE and DW MRl imaging will be performed in the same studies to compare the more specific PET assessments of metabolism, proliferation, angiogenesis, and apopotosis with the MRl perfusion and diffusion measurements that are more clinically available. This will further refine and validate the interpretation of MRl imaging response measured in Specific Aim #1 as well develop more specific PET imaging probes for future clinical trials. Together, the Specific Aims of this proposal will advance bi-directional translational research that enhances the knowledge of clinical MRl biomarkers for assessing early drug response in sarcoma therapy (bedside to bench) as well as develop novel PET imaging agents that are translatable to clinical trials and patient care (bench to bedside).

Public Health Relevance

This project will develop new imaging approaches using MRl and PET to non-invasively measure various aspects of tumor biology and pathophysiology in response to conventional and experimental chemotherapies. This will enable a powerful set of tools to evaluate treatment efficacy and ultimately improve the development of new drugs and clinical management of sarcoma patients.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ann Arbor
United States
Zip Code
Nakayama, Robert; Zhang, Yi-Xiang; Czaplinski, Jeffrey T et al. (2016) Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma. Oncotarget 7:16581-92
Goldstein, Seth D; Trucco, Matteo; Bautista Guzman, Wendy et al. (2016) A monoclonal antibody against the Wnt signaling inhibitor dickkopf-1 inhibits osteosarcoma metastasis in a preclinical model. Oncotarget 7:21114-23
Schaefer, Inga-Marie; Fletcher, Christopher Dm; Hornick, Jason L (2016) Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics. Mod Pathol 29:4-13
Mariño-Enríquez, Adrián; Bovée, Judith V M G (2016) Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma. Surg Pathol Clin 9:457-73
Tang, Qin; Moore, John C; Ignatius, Myron S et al. (2016) Imaging tumour cell heterogeneity following cell transplantation into optically clear immune-deficient zebrafish. Nat Commun 7:10358
Bobowski, Nina P; Baker, Laurence H (2016) The University of Michigan Sarcoma Survivorship Clinic: Preventing, Diagnosing, and Treating Chronic Illness for Improved Survival and Long-Term Health. J Adolesc Young Adult Oncol 5:211-4
Koehler, K; Liebner, D; Chen, J L (2016) TP53 mutational status is predictive of pazopanib response in advanced sarcomas. Ann Oncol 27:539-43
Bid, Hemant K; Phelps, Doris A; Xaio, Linlin et al. (2016) The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma. Mol Cancer Ther 15:1018-28
Simon, Priscilla S; Bardhan, Kankana; Chen, May R et al. (2016) NF-κB functions as a molecular link between tumor cells and Th1/Tc1 T cells in the tumor microenvironment to exert radiation-mediated tumor suppression. Oncotarget 7:23395-415
De Rienzo, Assunta; Archer, Michael A; Yeap, Beow Y et al. (2016) Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma. Cancer Res 76:319-28

Showing the most recent 10 out of 86 publications